Radioactive iodine therapy
Reading File
Finding Sources
Searching PubMed
"radioactive iodine" AND "thyroid"
Reading File
Reading File
Reading File
Reading File
Reading File
Here is a thorough overview of radioactive iodine (RAI) therapy drawn from multiple authoritative sources.
Radioactive Iodine (RAI) Therapy
Mechanism
RAI uses iodine-131 (¹³¹I), which is administered orally as sodium-¹³¹I solution. Because thyroid follicular cells are the only cells in the body that actively concentrate iodine (via the sodium-iodide symporter, NIS), the isotope is selectively taken up and incorporated into storage follicles. ¹³¹I emits beta particles with an effective half-life of 5 days and a tissue penetration range of 400-2000 µm (roughly 2 mm). This causes localized destruction through epithelial swelling and necrosis, follicular disruption, edema, and leukocyte infiltration - with minimal radiation exposure to surrounding tissues.
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- Current Surgical Therapy 14e
Indications
1. Hyperthyroidism (Graves' Disease)
RAI has been the preferred modality in the United States for Graves' disease - in a 2011 ATA survey, nearly 60% of North American endocrinologists chose it as first-line therapy. The goal is to render the patient permanently hypothyroid.
RAI is preferred for Graves' disease in:
- Comorbidities increasing surgical risk or limited life expectancy
- Liver disease (antithyroid drugs [ATDs] carry hepatotoxic risk)
- Major adverse reactions to ATDs
- Previously operated or externally irradiated necks
- Pulmonary hypertension or congestive heart failure
- Periodic paralysis
RAI is contraindicated in Graves' disease when:
- Pregnancy (absolute - destroys fetal thyroid)
- Breastfeeding
- Active moderate/severe Graves' orbitopathy (GO) - RAI can worsen eye disease; ATDs or surgery preferred
- Suspected or confirmed thyroid malignancy
Current Surgical Therapy 14e (ATA 2016 Guidelines)
2. Toxic Multinodular Goiter / Toxic Adenoma
RAI is preferred for elderly or high-surgical-risk patients. Contraindicated in pregnancy and if malignancy is suspected. For large compressive goiters or coexisting hyperparathyroidism, surgery is preferred.
3. Differentiated Thyroid Cancer (DTC): Post-thyroidectomy Adjuvant RAI
RAI plays a key role in papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) after total thyroidectomy. It has no role in poorly differentiated (PDTC), medullary (MTC), or anaplastic thyroid cancer (ATC), which do not concentrate iodine.
Two broad indications for RAI in DTC:
-
Remnant ablation - destroys residual normal thyroid tissue after thyroidectomy to:
- Improve specificity of serum thyroglobulin (Tg) and ¹³¹I scanning for detecting recurrence
- Prevent de novo cancer formation in remnant tissue
- Treat microscopic residual disease
-
Treatment of clinically detectable disease - for disease that cannot be addressed surgically (e.g., distant metastases)
Current risk-stratified approach (ATA 2022 RCT evidence):
- Low-risk DTC (intrathyroidal tumor < 4 cm, no high-risk histology, small multifocal): RAI provides no survival or recurrence benefit - NOT routinely recommended
- Intermediate-risk (> 4 cm, microscopic extrathyroidal extension, regional metastases, high-risk histology like tall cell, columnar, or insular subtypes): RAI may reduce death risk by ~29% (21,870-patient NCDB study)
- High-risk DTC (gross extrathyroidal extension, known distant metastases): RAI routinely recommended
Sabiston Textbook of Surgery; Cummings Otolaryngology
Preparation for RAI in Thyroid Cancer
- Low-iodine diet for 2-4 weeks before administration
- TSH stimulation (TSH > 30 mU/L) to maximize iodine uptake by residual thyroid/tumor cells - two methods:
- Thyroid hormone withdrawal (stop levothyroxine 3-4 weeks prior)
- Recombinant human TSH (rhTSH/Thyrogen) - equally effective, avoids hypothyroid symptoms; current data show rhTSH-mediated RAI is as effective as high-dose RAI with fewer adverse events
- Pre-treatment diagnostic scan with low-dose ¹³¹I (2-3 mCi) or ¹²³I - ¹²³I is preferred to avoid "thyroid stunning" (subtherapeutic ¹³¹I damages follicular cells and reduces uptake of subsequent therapeutic dose)
Dosing
| Indication | Typical Dose |
|---|---|
| Hyperthyroidism (Graves') | 12-15 mCi (renders hypothyroid in 2-3 months) |
| Thyroid remnant ablation (low-risk DTC) | 30-50 mCi |
| Intermediate/high-risk DTC treatment | 100-150 mCi |
| Distant metastases | 100-150 mCi (doses > 200 mCi not shown to be more effective) |
Repeat treatments are appropriate as long as iodine avidity is maintained and toxicity is acceptable. Maximum cumulative lifetime dose: ~600 mCi (controversial).
Preparation and Monitoring in Hyperthyroidism
- Stop ATDs 2-3 days before RAI and restart 3 days after (allows RAI incorporation)
- Consider beta-blockers for symptomatic patients and those at risk of thyrotoxic exacerbation (elderly, cardiopulmonary disease)
- Check TSH, total T3, free T4 at 1-2 months post-therapy
- Biochemical monitoring every 4-6 weeks for 6 months until stable on thyroid hormone replacement
- Do not repeat therapy for at least 6 months after initial dose
Adverse Effects
| Adverse Effect | Notes |
|---|---|
| Hypothyroidism | Expected and desired in hyperthyroidism; inevitable if multiple doses used |
| Sialadenitis | Salivary gland inflammation (dose-dependent) |
| Nasolacrimal duct obstruction | |
| Transient tumor/thyroid swelling | |
| Infertility | Dose-dependent, transient in most; precaution for 6-12 months post-therapy |
| Secondary malignancies | Particularly leukemia - dose-dependent; risk is real but low |
| Worsening of Graves' orbitopathy | Glucocorticoid prophylaxis recommended if RAI used in mild active GO |
Decades of clinical experience (> 50 years) have not confirmed feared risks of radiation-induced genetic damage or leukemia in hyperthyroidism doses, though risks increase with higher cumulative doses used in cancer treatment.
Absolute Contraindications
- Pregnancy (crosses placenta, destroys fetal thyroid)
- Breastfeeding (secreted in breast milk)
- Active moderate-to-severe Graves' orbitopathy
- Suspected or confirmed thyroid malignancy (when treating hyperthyroidism)
- Inability to comply with radiation safety guidelines
Post-Treatment Scanning (Thyroid Cancer)
A whole-body post-treatment scan is performed within 1 week after therapeutic RAI to visualize potential metastases that may not have been detected on pre-treatment scans. Post-treatment scans are more sensitive than diagnostic scans due to the higher dose administered.
Recent Evidence (2024-2025)
- A 2024 meta-analysis (PMID 38870537) examined RAI in thyroid cancer coexisting with Hashimoto's thyroiditis, noting this is an important clinical scenario affecting RAI efficacy.
- A 2024 systematic review (PMID 39541671) addressed adjuvant RAI in tall cell subtype PTC - a high-risk variant where RAI benefit remains under study.
- An ATA-endorsed 2022 RCT confirmed no benefit of RAI in low-risk PTC after total thyroidectomy, reinforcing the current trend toward de-escalation of RAI in low-risk disease.
Summary: RAI is a highly effective, organ-specific therapy whose main strength is the thyroid's unique iodine-concentrating mechanism. In hyperthyroidism, it delivers definitive ablation with minimal systemic toxicity. In thyroid cancer, its role has become increasingly risk-stratified - reserved for intermediate-to-high-risk DTC while being omitted in low-risk disease based on strong recent evidence.
Radioactive iodine
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.